Unité d'investigation clinique de Neurologie Rez-de-jardin, Bloc Hopital CHU Pontchaillou
Welcome,         Profile    Billing    Logout  
 2 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
drapier, sophie
LIGHTHOUSE, NCT05418673 / 2022-000747-77: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Terminated
3
7
Europe, US
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
07/23
07/23
NCT04265209 / 2019-000247-27: [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor

Recruiting
3
152
Europe
SPECT, PET
Zionexa
Parkinson Disease, Essential Tremor
09/24
12/24
EARLY-PUMP, NCT02864004: Apomorphine Pump in Early Stage of Parkinson's Disease

Active, not recruiting
3
134
Europe
Apomorphine, Apokinon, Best Medical Treatment
Rennes University Hospital
Parkinson's Disease
12/23
01/25
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
PIMPARK, NCT03947216: Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

Completed
2
117
Europe
Active drug: pimavanserin 17mg (2 strength tablets), Placebo: 2 tablets containing same excipients except active compound, Assessment of severity of ICD (impulse control disorders), Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors, Assessment of quality of life, Assessment of depression, Assessment of cognition, Assessment of severity of Parkinson Disease, Blood analysis, Cardiac monitoring
University Hospital, Strasbourg, France, NS-PARK, EUCLID Clinical Trial Platform, F-CRIN, ACADIA Pharmaceuticals Inc.
Parkinson Disease
04/24
06/24
LUMA, NCT05348785 / 2021-004849-20: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

Recruiting
2
640
Europe, Canada, Japan, US, RoW
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
12/25
12/25
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Active, not recruiting
2
237
Europe, Canada, US
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Bial R&D Investments, S.A.
Parkinson's Disease
03/26
07/26
RETRO-PIMPARK, NCT06754553: Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

Not yet recruiting
N/A
100
Europe
Assessment of severity of ICD (impulse control disorders), Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors, Assessment of quality of life, Assessment of depression, Assessment of cognition, Assessment of severity of Parkinson Disease, Cardiac monitoring
University Hospital, Strasbourg, France, NS-PARK Network, EUCLID Clinical Trial Platform, F-CRIN
Parkinson Disease
02/26
02/26
PERSO-PERF, NCT06080399: Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease

Recruiting
N/A
70
Europe
Continuous subcutaneous apomorphine infusion (CSAI)
University Hospital, Toulouse, ELIVIE France, EVER Pharma France SAS, NHC SAS, France, Orkyn', ETPARK Association, Toulouse, France
Parkinson Disease
04/26
04/26
KESTENS, Francoise
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Active, not recruiting
2
237
Europe, Canada, US
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Bial R&D Investments, S.A.
Parkinson's Disease
03/26
07/26

Download Options